Phytopharm Begins Level-I Program

Global Finance, Oct 2004

Cambridge, UK-based Phytopharm, which develops plant-based medicines and manufactures them to pharmaceutical standards, established a Level-I ADR program with Bank of New York as depositary.

The Level-I program is the first step toward listing Phytopharm's securities on Nasdaq, according to the company, which has hired Global Markets Capital Group to manage the listing process.

Phytopharm CEO Richard Dixey says US investors are interested in the company's products for obesity, Alzheimer's disease and Lou Gehrig's disease.

Each Phytopharm ADR represents two ordinary shares, which are traded on the London Stock Exchange.

Copyright Global Finance Media Inc. Oct 2004
Provided by ProQuest Information and Learning Company. All rights Reserved
 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement

Content provided in partnership with ProQuest